润达医疗
(603108)
| 流通市值：93.33亿 | | | 总市值：93.33亿 |
| 流通股本：6.04亿 | | | 总股本：6.04亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,510,505,870.23 | 6,998,529,976.26 | 5,268,459,587.79 | 3,470,487,876.09 |
| 营业收入 | 1,510,505,870.23 | 6,998,529,976.26 | 5,268,459,587.79 | 3,470,487,876.09 |
| 二、营业总成本 | 1,504,546,302 | 7,099,474,285.35 | 5,307,471,760.12 | 3,514,567,613.8 |
| 营业成本 | 1,159,431,877.16 | 5,501,628,423.01 | 4,134,821,387.13 | 2,743,783,854.18 |
| 税金及附加 | 6,964,559.32 | 29,199,696.24 | 21,422,146.27 | 14,232,635.04 |
| 销售费用 | 156,681,465.68 | 748,601,097.65 | 562,371,124.47 | 369,623,684.99 |
| 管理费用 | 92,875,139.62 | 438,515,506.84 | 303,152,989.12 | 200,072,067.55 |
| 研发费用 | 25,928,682.72 | 108,013,762.47 | 82,554,832.89 | 55,211,793.34 |
| 财务费用 | 62,664,577.5 | 273,515,799.14 | 203,149,280.24 | 131,643,578.7 |
| 其中:利息费用 | 60,939,111.53 | 278,931,171.45 | 208,662,636.08 | 140,429,424.15 |
| 其中:利息收入 | 1,488,229.02 | 10,980,948.03 | 10,040,351.09 | 8,659,031.75 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 12,478,846.42 | 20,794,519.81 | 66,886,817.47 | 47,447,216.74 |
| 资产处置收益 | -1,481,788.22 | 3,119,148.21 | 893,530.01 | -958,792.77 |
| 资产减值损失(新) | -266,653.6 | -208,737,137.88 | -70,339.94 | -45,795.63 |
| 信用减值损失(新) | -54,742,104.55 | -196,535,945.86 | -110,956,271.25 | -73,969,820.68 |
| 其他收益 | 2,685,984.03 | 32,047,685.39 | 24,748,191.11 | 20,117,157.69 |
| 四、营业利润 | -35,366,147.69 | -450,256,039.42 | -57,510,244.93 | -51,489,772.36 |
| 加:营业外收入 | 178,091.31 | 5,853,029.53 | 3,069,154.88 | 1,798,808.11 |
| 减:营业外支出 | 843,523.79 | 16,234,218.1 | 7,346,697.45 | 3,369,511.22 |
| 五、利润总额 | -36,031,580.17 | -460,637,227.99 | -61,787,787.5 | -53,060,475.47 |
| 减:所得税费用 | 9,942,365.08 | 57,513,652.47 | 64,415,776.3 | 46,421,694.58 |
| 六、净利润 | -45,973,945.25 | -518,150,880.46 | -126,203,563.8 | -99,482,170.05 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -45,973,945.25 | -518,150,880.46 | -126,203,563.8 | -99,482,170.05 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -53,561,218.35 | -548,393,978.51 | -162,691,533.55 | -120,652,208.04 |
| 少数股东损益 | 7,587,273.1 | 30,243,098.05 | 36,487,969.75 | 21,170,037.99 |
| 扣除非经常损益后的净利润 | -53,161,947.11 | -565,822,548.63 | -178,282,052.02 | -134,139,032.15 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.09 | -0.91 | -0.27 | -0.2 |
| (二)稀释每股收益 | -0.09 | -0.91 | -0.27 | -0.2 |
| 八、其他综合收益 | 1,343,539.1 | -10,279,338.19 | -285,439.17 | -1,094,094.88 |
| 归属于母公司股东的其他综合收益 | 1,251,318.78 | -9,811,024.62 | -262,060.32 | -1,008,558.78 |
| 九、综合收益总额 | -44,630,406.15 | -528,430,218.65 | -126,489,002.97 | -100,576,264.93 |
| 归属于母公司股东的综合收益总额 | -52,309,899.57 | -558,205,003.13 | -162,953,593.87 | -121,660,766.82 |
| 归属于少数股东的综合收益总额 | 7,679,493.42 | 29,774,784.48 | 36,464,590.9 | 21,084,501.89 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-30 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |